Aegerion Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aegerion Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013164
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aegerion Pharmaceuticals Inc (Aegerion) is a pharmaceutical company that develops therapies for patients with debilitating often fatal and rare diseases. The company provides therapeutics to treat severe inherited lipid disorders. Its therapeutic focus comprise homozygous familial hypercholesterolemia (HoFH), the most severe form of familial hypercholesterolemia. Aegerion offers microsomal triglyceride transfer protein inhibitors, leptin analog replacement therapy and products that reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density lipoprotein cholesterol. Its are used in low-fat diet and other lipid-lowering treatments and in the treatment of complications of leptin deficiency. The company distributes its products across the US. Aegerion is headquartered in Cambridge, Massachusetts, the US.

Aegerion Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 10
Licensing Agreements 12
Aegerion Pharma Enters into Licensing Agreement with Amryt Pharma 12
Equity Offering 13
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 13
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 15
Aegerion Pharma Completes Public Offering Of US$53 Million 17
Aegerion Pharma Completes IPO Of US$54.6Million 19
Debt Offering 21
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 21
Acquisition 22
QLT Acquires Aegerion Pharma 22
Aegerion Pharmaceuticals Inc – Key Competitors 24
Aegerion Pharmaceuticals Inc – Key Employees 25
Aegerion Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Nov 03, 2016: Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results 27
Aug 09, 2016: Aegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results 29
May 16, 2016: Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results 31
Feb 25, 2016: Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results 33
Jan 11, 2016: Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates 36
Corporate Communications 37
Jan 07, 2016: Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer 37
Other Significant Developments 38
Nov 21, 2017: Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice 38
Sep 19, 2016: Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals by Establishing a Preferred Provider Agreement 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aegerion Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Aegerion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 10
Aegerion Pharma Enters into Licensing Agreement with Amryt Pharma 12
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 13
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 15
Aegerion Pharma Completes Public Offering Of US$53 Million 17
Aegerion Pharma Completes IPO Of US$54.6Million 19
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 21
QLT Acquires Aegerion Pharma 22
Aegerion Pharmaceuticals Inc, Key Competitors 24
Aegerion Pharmaceuticals Inc, Key Employees 25

★海外企業調査レポート[Aegerion Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Athene Annuity & Life Assurance Company of New York:企業の戦略・SWOT・財務情報
    Athene Annuity & Life Assurance Company of New York - Strategy, SWOT and Corporate Finance Report Summary Athene Annuity & Life Assurance Company of New York - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • Northwest Territories Power Corp:企業の発電所・SWOT分析2018
    Northwest Territories Power Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Tyser & Co Ltd:企業の戦略的SWOT分析
    Tyser & Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Capitol Health Ltd (CAJ):企業の財務・戦略的SWOT分析
    Summary Capitol Health Ltd (Capitol Health) is a diagnostic imaging service provider. The company offers services such as bone densitomety, computer tomography, cone beam CT, CT angiography, doppler, echocardiography, fluoroscopy, general X-ray, magnetic resonance imaging, mammography, nuclear medic …
  • Dairyland Power Cooperative:企業の戦略的SWOT分析
    Dairyland Power Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Landesbank Berlin Holding Ag
    Landesbank Berlin Holding Ag - Strategy, SWOT and Corporate Finance Report Summary Landesbank Berlin Holding Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cytune Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Cytune Pharma SAS (Cytune) is a health care product developer that develops immunotherapeutic agents for the treatment of cancer and infectious diseases. The company’s product portfolio includes recombinant proteins and monoclonal antibodies. Its CYP0150 is a recombinant protein, which decre …
  • Sutter Health:企業の戦略的SWOT分析
    Sutter Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Crown Bioscience Inc:企業のM&A・事業提携・投資動向
    Crown Bioscience Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Crown Bioscience Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Oxford Performance Materials Inc-医療機器分野:企業M&A・提携分析
    Summary Oxford Performance Materials Inc (OPMI), a subsidiary of Arkema Inc is a chemical company that manufactures thermoplastic polymers. The company’s products include proprietary polyether ketone ketone formulations, additives, complex assemblies, biomedical raw materials, biomedical parts, robo …
  • ERG Renew SpA:企業の戦略的SWOT分析
    ERG Renew SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Tillotts Pharma AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Tillotts Pharma AG (Tillotts) a subsidiary of Zeria Pharmaceutical Co Ltd is a healthcare solution provider that develops, licenses and markets pharmaceutical products, medical devices and diagnostics in the field of gastroenterology. The company’s products are used for the treatment of vari …
  • Bank of Baroda:企業のM&A・事業提携・投資動向
    Bank of Baroda - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Baroda Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Ameresco Inc (AMRC):電力:M&Aディール及び事業提携情報
    Summary Ameresco, Inc. (Ameresco) provides comprehensive energy services, including energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions. It also offers energy infrastructure facility upgrade; and development, construction and operation of renewable energy …
  • CryoTherapeutics Gmbh-医療機器分野:企業M&A・提携分析
    Summary CryoTherapeutics GmbH (CryoTherapeutics) is a medical equipment company that offers systemic drug based approach in combination with a localised device-based therapy. The company’s proprietary cryotherapy system is used for the treatment of coronary artery disease that causes heart attacks. …
  • Lloyds Banking Group Plc:企業のM&A・事業提携・投資動向
    Lloyds Banking Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lloyds Banking Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Mmi Holdings Ltd.:企業の戦略・SWOT・財務分析
    Mmi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mmi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Fresenius Kabi AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and …
  • AcuFocus Inc-医療機器分野:企業M&A・提携分析
    Summary AcuFocus Inc (AcuFocus) is a medical device company that develops and markets technologies for the improvement of near vision. The company's products include kamra inlay, small aperture lens and acutarget HD instrument. It offers near vision solutions and develops ophthalmic medical devices. …
  • EMS SA:製薬・医療:M&Aディール及び事業提携情報
    Summary EMS SA (EMS) is a pharmaceutical company, which is focused in the development of products for improvement of health and well-being of the population. It operates in prescription segments generics, branded pharmaceuticals, OTC and hospital. It has presence in the US market through Brace Pharm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆